Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Holdings Boosted by Privium Fund Management B.V.

Privium Fund Management B.V. raised its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 8.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 432,760 shares of the biotechnology company’s stock after purchasing an additional 35,110 shares during the quarter. Rocket Pharmaceuticals comprises approximately 0.8% of Privium Fund Management B.V.’s investment portfolio, making the stock its 21st biggest holding. Privium Fund Management B.V. owned 0.41% of Rocket Pharmaceuticals worth $2,887,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in RCKT. Covestor Ltd increased its stake in shares of Rocket Pharmaceuticals by 33,166.7% in the fourth quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 1,990 shares during the period. Signaturefd LLC increased its stake in shares of Rocket Pharmaceuticals by 83.6% in the first quarter. Signaturefd LLC now owns 9,024 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 4,108 shares during the period. Virtus ETF Advisers LLC increased its stake in shares of Rocket Pharmaceuticals by 40.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,656 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 1,628 shares during the period. LJI Wealth Management LLC acquired a new stake in shares of Rocket Pharmaceuticals in the first quarter valued at approximately $80,000. Finally, Victory Capital Management Inc. increased its stake in shares of Rocket Pharmaceuticals by 16.1% in the first quarter. Victory Capital Management Inc. now owns 11,929 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,658 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on RCKT. Cantor Fitzgerald raised their price target on shares of Rocket Pharmaceuticals from $20.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, May 16th. Leerink Partnrs lowered shares of Rocket Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 27th. Canaccord Genuity Group lowered their price objective on shares of Rocket Pharmaceuticals from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, July 25th. Chardan Capital lowered their price objective on shares of Rocket Pharmaceuticals from $17.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, July 24th. Finally, BMO Capital Markets lowered their price objective on shares of Rocket Pharmaceuticals from $30.00 to $8.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.87.

Rocket Pharmaceuticals Trading Down 2.0%

Shares of NASDAQ:RCKT opened at $2.99 on Friday. The stock has a market capitalization of $319.30 million, a price-to-earnings ratio of -1.14 and a beta of 0.65. Rocket Pharmaceuticals, Inc. has a 1-year low of $2.19 and a 1-year high of $22.01. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.19 and a current ratio of 9.19. The company has a 50 day moving average price of $2.97 and a 200 day moving average price of $6.43.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.02. During the same quarter in the prior year, the firm earned ($0.66) EPS. On average, research analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.